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Abstract: The Trk family of receptors play a wide variety of roles in physiological and 
disease processes in both neuronal and non-neuronal tissues. Amongst these the TrkB 
receptor in particular has attracted major attention due to its critical role in signalling for 
brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT3) and neurotrophin-4 
(NT4). TrkB signalling is indispensable for the survival, development and synaptic 
plasticity of several subtypes of neurons in the nervous system. Substantial evidence has 
emerged over the last decade about the involvement of aberrant TrkB signalling and its 
compromise in various neuropsychiatric and degenerative conditions. Unusual changes in 
TrkB signalling pathway have also been observed and implicated in a range of cancers. 
Variations in TrkB pathway have been observed in obesity and hyperphagia related 
disorders as well. Both BDNF and TrkB have been shown to play critical roles in the 
survival of retinal ganglion cells in the retina. The ability to specifically modulate TrkB 
signalling can be critical in various pathological scenarios associated with this pathway. In 
this review, we discuss the mechanisms underlying TrkB signalling, disease implications 
and explore plausible ameliorative or preventive approaches. 
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Neurogenic locus notch homolog protein 2; JNK, c-Jun N-terminal kinase. 
1. Introduction 
The Trk family of receptors includes TrkA, TrkB and TrkC which are instrumental in carrying out 
the cellular effects of neurotrophins. P75NTR, a member of the tumour necrosis receptor superfamily 
exhibits some structural similarities to Trk family of receptors and interacts with members of the Trk 
family including TrkB receptor and influences its signalling. There is a cross talk between various 
members of the Trk family and p75NTR by formation of the chimeric heteromeric complexes [1]. 
TrkB (EC 2.7.10.1) (NTRK2) molecule, in particular, has attracted significant attention in recent years 
because of its involvement in several important biological processes. TrkB acts as a receptor for  
brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT4) ligands. Neurotrophin-3 (NT3) in 
addition to binding and activating TrkC, can also bind TrkB with reduced affinity and plays a role in 
regulating neuronal survival [1]. The tyrosine kinase receptors are activated upon binding to the 
cognate neurotrophin ligand and undergo dimerization with the unliganded monomeric form believed 
to be in equilibrium with the phosphorylated dimeric state [2]. This dynamic equilibrium between 
monomeric and dimeric forms may be important to regulate downstream intracellular biochemical 
actions of neurotrophins and their receptors. TrkB is a single pass type 1 membrane protein and may 
be incorporated in endosomes upon ligand binding [3,4]. This receptor contains a protein kinase 
domain, two leucine rich repeats and two Ig-like C2 set domains. TrkB is expressed in both the central 
(CNS) and peripheral nervous systems (PNS). In the CNS, a high TrkB expression is observed in 
cerebral cortex, hippocampus, thalamus, choroid plexus, and granular layer of the cerebellum, brain 
stem, retina and the spinal cord [5]. In the PNS, it is expressed in the cranial ganglia, vestibular 
system, sub-maxillary glands and the dorsal root ganglia [5]. TrkB is widely expressed in the fetal 
brain. TrkB expression is also detected in a variety of other tissues like skeletal muscles, kidneys  
and pancreas. Truncated forms of TrkB lacking the tyrosine kinase domain are known to be distributed 
in heart, ovary and spleen tissues [6]. TrkB expression has also been observed in the Meissner 
corpuscles [7].  
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2. Biological Functions of TrkB Signalling 
Trk receptors possess an intracellular tyrosine kinase domain which upon phosphorylation recruits 
signalling intermediates and initiate intracellular signalling cascades (Figure 1). The tyrosine 
phosphorylation is triggered by the binding of neurotrophins leading to recruitment of pleckstrin 
homology (PH) and SH2 domain containing proteins such as FRS2, Shc, SH2B and SH2B2 that 
regulate distinct overlapping signalling cascades [8,9]. TrkB regulates growth and survival of the cells 
by controlling the Ras-PI3K-Akt signalling cascade. There is sufficient evidence that in the neurons, 
TrkB activates the GRB2-Ras-MAPK-Erk signalling and regulates the neuronal differentiation 
including neurite development [10,11]. TrkB activation regulates synaptic plasticity by promoting the 
phospholipase Cγ (PLCγ) mediated pathways through downstream protein kinase C signalling [12]. 
There is a cross-talk of the TrkB receptor signalling with small G proteins as well, including Ras and 
Rap-1, and it also interacts with Tiam1 protein leading to Rac activation [13]. TrkB has also been 
found to interact with p62 and ankyrin rich membrane spanning (ARMS) proteins in the cells leading 
to modulation of the kinetics of MAPK/Erk activation [14,15]. TrkB is involved in the transcription 
regulation through its effects on cell cycle inhibitor p21 (Cip21), involving helix-loop-helix  
proteins [16]. The transcription factor E47 upon phosphorylation by Mixed lineage kinase (MLK2) 
leads to inhibition of the E47 induced TrkB transcription in the neuronal cells [17]. TrkB also plays a 
role in neurotrophin-dependent calcium signalling in the glial cells [18–21] (Figure 1). 
Figure 1. Schematic representation of the BDNF/TrkB receptor signalling axis and its 
downstream cellular effects. The binding of neurotrophic factors leads to auto-phosphorylation 
of the receptor intracellular domain. Cross-talk with other receptors and its regulation is 
shown. The internalization and transport of BDNF/TrkB in cells through endosomes is 
represented diagrammatically. P, Phosphorylation; Cav, Caveolin; IP3, Inositol tri-phosphate; 
CaM, Calmodulin.  
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The pan-neurotrophin receptor, p75NTR promotes distinct signalling pathways in the cells that in 
most cases oppose but sometimes coordinate with TrkB promoted pathways (Figure 1). Another way 
of P75NTR modulating TrkB actions is through its capability to influence the receptor conformation 
thereby altering TrkB specificity and affinity with neurotrophins under normal and pathological 
conditions [12].  
Various isoforms of Caveolin protein have been shown to interact with TrkB and p75NTR. 
Caveolar rafts in the cell membrane may further provide a platform for the interaction of these two 
receptors [22]. BDNF binding in fact induces a mobilisation of the TrkB.FL into the cholesterol rich 
lipid raft regions of neuronal plasma membrane [23]. The tyrosine phosphatase PTPN11 (Shp2)  
is found to play an important regulatory role in neurotrophin signalling [24]. This can be compared to 
the regulation of insulin receptor signalling by protein tyrosine phosphates 1-B activity in 
photoreceptors [25,26]. Cellular Ca2+ influx leads to loss of BDNF induced activation of Ras and its 
downstream effectors MAPK/Erk and Akt. This is the result of enhanced association of Shp2 with 
TrkB receptor, resulting in its deactivation. Shp2 deletion in neuronal cultures reversed TrkB inhibition 
and promoted neuronal survival [27,28]. In RGCs, Shp2 binds to the TrkB receptor and plays a role in 
negatively regulating its activity. The inhibition of Shp2 restores TrkB activity in cells exposed to 
excitotoxic and oxidative stress. Caveolin-1 and 3 isoforms participate in this enhanced TrkB-Shp2 
interaction illustrating a molecular basis of Shp2 mediated TrkB deactivation which leads to RGC 
degeneration in glaucoma [29,30]. Glucocorticoids have been shown to suppress Shp2-TrkB 
interaction thereby inhibiting the BDNF stimulated MAPK/Erk pathway [31] (Figure 1).  
The vital role of TrkB in physiological functions is evident from the fact that TrkB−/− mice die 
within few days after birth and display serious abnormalities in their nervous system. These mice 
exhibit loss of motor neurons, small dorsal root ganglion, small facial motor nucleus as well as a small 
trigeminal ganglion [32]. A reduced cell density is observed in cochlear ganglia [33]. TrkB pathway  
is vital in neural development and maintenance through differentiation and neurogenesis. Its  
disruption leads to unusual Purkinje cell dendrite morphology, atypical cerebellum development and  
diminutive geniculate and nodose ganglia [34]. It plays a role in synaptic plasticity and function [12,35]. 
BDNF/TrkB signalling is important in modulating presynaptic kainate receptor activity in the 
developing brain and in building up new synaptic connections [36]. It has a positive effect on learning and 
memory by regulating both short term synaptic function and hippocampal long-term potentiation [9]. 
TrkB signalling is indicated in both the production and maintenance of pain caused by nerve or tissue 
injury [37]. Owing to the fact that TrkB is well expressed in Meissner corpuscles, TrkB−/− mice exhibit 
diminished response to tactile stimuli [32].  
TrkB is a marker as well as mediator of carcinogenesis and metastasis [38]. Its expression rapidly 
changes in neuroblastoma cells on exposure to various treatments [39]. TrkB stimulates VEGF 
expression though the Phosphatidyl inositol 3-kinase (PI3K) pathway in neuroblastoma cells [40], 
indicating its possible role in angiogenesis. It cross-activates the Ret receptor and promotes 
phosphorylation of its intracellular domain. Inhibiting either TrkB or Ret leads to failure in 
differentiation of the neuroblastoma cells [41]. TrkB signalling is implicated in regulating protein 
expression and protein targeting in the neurons. TrkB receptor also cross-talks with EGFR and 
enhanced EGFR signalling was observed in ovarian cancer cells in response to BDNF binding leading 
to cell survival signalling activation [42]. TrkB stimulation triggers NF-κB activity through PLCγ1 
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activation and enhances cell survival signalling which in turn leads to anoikis suppression [43]. An 
increased c-fos expression in TrkB expressing cells upon BDNF stimulation indicates an increased 
survival activity, which is lost upon pharmacologically inhibiting TrkB. c-fos is a proto-oncogene and 
a transcription factor that promotes cellular proliferation. It’s upregulation is believed to be mediated 
in part through activation of both MAPK and PI3K/Akt pathways by TrkB [44]. Both follicle 
stimulating hormone and hepatocyte growth factor act on the cells by promoting the expression of 
TrkB receptor [43,45]. 
In the retina, TrkB is well expressed early during the development and is important in the formation 
of inner retinal network [46]. TrkB activation leads to an enhanced PI3K/Akt and Erk1/2 signalling in 
the retinal ganglion cells (RGCs) and Erk1/2 in particular, appears to be responsible for promoting the 
survival of RGCs [47]. TrkB mediates BDNF internalization and its retrograde transport from the 
retina to isthmo-optic nucleus [48]. TrkB signalling programmes the differentiation of retinal 
progenitor cells to the photoreceptors and both BDNF and TrkB have been shown to be involved in 
mediating retinal neuroprotection [49–51]. Rod photoreceptors are conspicuous in that these lack 
TrkB, but TrkB signalling may be indirectly supported through the Müller cells and retinal pigment 
epithelium in the retina. TrkB signalling is also important in the conversion of Müller glia to 
photoreceptors during development [52,53]. A truncated isoform of TrkB receptor, TrkB.T1 in Muller 
cells is implicated in BDNF-mediated photoreceptor protection against light damage [54]. TrkB along 
with its ligands is observed to localise to endosomes along with downstream signalling effectors, such 
as Shc and PLC-γ1. Cellular transport of these endosomes makes it possible for TrkB to travel through 
the cell body, axons and nucleus [12]. This may be the mechanism of BDNF/TrkB transport along the 
axons of the optic nerve. TrkB promotes PSD-95 localisation to synapses in the visual cortex  
along with protein kinase M zeta after eye-opening during development indicating its role in the 
regulation of synaptic plasticity along visual pathway and implications in developmental disorders of  
brain [55] (Figure 1).  
3. Role of TrkB Splice Variants  
The TrkB locus is in chromosome 9 in humans and is mainly expressed in three splice variants. 
TrkB full length (TrkB F.L.) possesses an intracellular tyrosine kinase domain and rapidly transmits 
the effects of neurotrophin binding to downstream network. Alternative splicing of the primary 
transcript produces truncated TrkB isoforms (T1 and T-shc in humans; T1 and T2 in rat) that lack the 
intracellular tyrosine kinase domain and cannot elicit rapid intracellular signalling [3,56]. TrkB-T-TK 
(Uniprot: Q16620-6) is another isoform in which C-terminal part (87 residues) is missing while a large 
part of the amino (156 residues) and carboxy-terminal (345 residues) are missing in TrkB-N-T1 
(Uniprot: Q16620-7), with both isoforms exhibiting some sequence variations from the canonical TrkB 
sequence (Uniprot: Q16620). TrkB-T1 is predominantly expressed in the brain but also detected in 
heart, kidney and pancreas. Isoform TrkB-T-Shc is mainly expressed in the brain [3,57]. T1 can 
behave as a dominant negative isoform by competing with neurotrophins and form heterodimers with 
the TrkB full-length (TrkB.FL) [58]. Increased expression of T1 in injury or seizure is believed to 
sequester and limit the availability of BDNF, thereby preventing axonal regeneration at the site of 
injury [59]. The dominant negative behaviour is just one of the several functions of TrkB.T1. TrkB.T1 
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may additionally, sequester and translocate BDNF, induce filopodia and neurite outgrowth, stimulate 
intracellular signalling, regulate Rho GTPase signalling, and modify cytoskeletal structures [60]. TrkB 
regulates the dendritic development pattern and may play critical roles during development; TrkB.FL 
plays a more prominent role in increasing proximal dendritic branching whereas truncated TrkB is 
involved in the elongation of distal dendrites [61]. BDNF application produces rapid signals in neurons 
through TrkB.FL and the voltage gated sodium channel [62,63] while astrocytes predominately 
express TrkB.T1 and respond to BDNF by releasing calcium from the intracellular stores [64].  
4. Involvement of TrkB Signalling in Disease Processes 
An increasing number of studies have suggested the involvement of BDNF/TrkB in various 
pathological conditions. BDNF/TrkB dysregulation leads to cellular proliferative changes as well as 
degenerative and behavioural changes in the brain (Figure 2).  
Figure 2. TrkB signalling alterations in various disease conditions. An increase (right) or 
decrease (left) of TrkB expression or its signalling may lead to a range of pathological 
conditions indicating the significance of the maintenance of a fine equilibrium of the TrkB 
signalling pathway. TrkB (space-filled)-BDNF (wire-frame) dimeric complex. AD, 
Alzheimer’s Disease; HD, Huntington’s Disease; PD, Parkinson’s Disease; SIDS, Sudden 
Infant Death Syndrome; RGC, Retinal Ganglion Cell; MS, Multiple Sclerosis; SCC, 
Squamous Cell Carcinoma. 
 
4.1. TrkB in Proliferative Disorders 
TrkB is indicated to play a role in various types of malignancies including those of neuroendocrinal 
origin [65]. A high expression of TrkB is associated with neuroblastomas and co-operativity has been 
observed between TrkB and c-Met receptors in promoting the neuroblastoma invasiveness [66,67]. 
Differences in the gene expression pattern of TrkB lead to differential phenotypes of TrkB expressing 
neuroblastomas [68]. TrkB activity in general, plays an important role in tumor formation  
and metastasis [69]. TrkB is a strong suppressor of anoikis, which makes it an important factor  
in metastasis [70]. Several naturally occurring mutations in TrkB have been identified in lung 
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adenocarcinoma patients [71]. BDNF/TrkB signalling promotes tumour cell survival in multiple 
myeloma by activating MAPK and PI3K/Akt pathways [72]. TrkB has also emerged as an important 
prognostic marker in gastric cancer [73]. TrkB forms a significant component of head and neck 
squamous cell carcinoma and constitutes a target for potential therapy [74]. Its activation is implicated 
in non-small cell lung cancer and promotes proliferation of adenocarcinomic human alveolar basal 
epithelial cells and metastasis via the Pyk2/ERK pathway [75]. Abnormal TrkB regulation leads to 
pathological lesions observed in pulmonary fibrosis, fibroblast proliferation and alveolar cell 
hyperplasia [76].  
4.2. TrkB in Psychiatric Disorders 
Molecular events associated with TrkB may play a role in predisposition to depression and other 
psychiatric disorders as well as drug abuse. TrkB may in particular play an important role in the 
susceptibility to geriatric depression [77]. TrkB levels in the serum of clinically depressed patients are 
reported to be higher compared to that of the normal individuals [78]. Several TrkB mutations have 
been linked to the progression of anxiety disorders [79]. Reduction of TrkB-mediated signalling  
may play a role in the pathophysiology of schizophrenia and bipolar disorder [80]. Schizophrenia and 
other psychological disorders have been linked with sharp decline in TrkB.FL transcripts in  
the hippocampus [81,82]. The report that TrkB mRNA in the prefrontal cortex is significantly 
diminished in the suicide ideation patients has generated a considerable interest to study its role in the 
suicide behaviour [83]. TrkB is also indicated to determine the susceptibility towards nicotine 
dependence [84]. It has been shown to play a role in imparting alcohol addiction amongst Caucasian 
populations [85].  
4.3. TrkB in Neurodegenerative Disorders 
Loss of TrkB signalling is reported to play roles in pathogenesis of Alzheimer’s, Huntington’s and 
other neurodegenerative disorders. It is proposed to be a susceptibility gene contributing to 
Alzheimer’s disease pathology [86]. TrkB signalling helps in the maintenance of the nigrostriatal 
system; deficiency may contribute to the progression of Parkinson's disease [87]. Interestingly, TrkB 
stimulation in astrocytes drives nitric oxide production which may promote neurodegeneration in  
brain [88]. TrkB signalling is involved in the regulation of peripheral T cell apoptosis in multiple 
sclerosis [89]. Alterations in TrkB signalling contribute to an increased vulnerability to autism and 
impair synaptic plasticity in a mouse model of fragile-X syndrome [90,91]. TrkB expression changes 
indicate that it may have a role in Rett syndrome pathology [92]. Neuroprotective functions of the 
BDNF/TrkB axis may be reduced in the respiration nuclei in sudden infant death syndrome (SIDS) 
cases [93]. An increase in TrkB expression is associated with increased seizure susceptibility and 
epileptogenesis [94]. In glaucoma, loss of TrkB signalling leads to preferential degeneration of  
RGCs [95,96]. Transport obstruction in the optic nerve inhibits the retrograde delivery of TrkB from 
the brain to RGCs resulting in TrkB signalling deficit and eventual cell death [97,98]. Intra-ocular 
pressure elevation leads to increase in TrkB labelling behind the optic nerve head region and its diminution 
in RGCs indicating that RGCs may undergo degeneration due to its reduced availability [29,99]. 
Lingo-1 protein which is a negative regulator of neuronal survival and axonal regeneration and a 
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member of Nogo66/p75NTR complex has been shown to interact with TrkB receptor in retina and 
negatively regulate its phosphorylation in ocular hypertension [100,101].  
4.4. TrkB in Other Disorders 
Several studies support the involvement of BDNF and TrkB in vulnerability to eating disorders. 
This may be due to the involvement of BDNF/TrkB signalling axis in brain in the regulation of  
eating behaviour and attitudes or perception towards body weight or shape. TrkB has been implicated 
in promoting genetic susceptibility to anorexia nervosa, minimum body mass index and harm 
avoidance [102]. Defects in TrkB are also a cause of obesity hyperphagia and developmental delay 
(OHPDD) disorder in patients. OHPDD is a disorder characterized by early-onset obesity, hyperphagia 
and severe developmental delay in speech and motor function [4]. Mice heterozygous for BDNF 
develop obesity related to hyperphagia while BDNF administration in rats promotes weight reduction 
by causing loss of appetite. Mutations in TrkB result in impaired ligand induced phosphorylation and 
downstream Erk1 activation leading to obesity related disorders [4].  
TrkB supports oocyte-to-granulosa cell communication by promoting signalling between JAGGED1 
and NOTCH2 leading to early follicle growth [103]. Distribution of all types of TrkB receptor 
transcripts has been observed in oocytes and granulosa cells [104]. Alterations in placental TrkB are 
observed in pregnancy associated with maternal under nutrition, type-1 diabetes and disturbances of 
foetal growth [105]. An increased expression of TrkB in endometrium has been observed in conditions 
associated with endometriosis [106] (Figure 2). 
5. Therapeutic Potential of TrkB Pathway Modulation 
Molecular strategies to regulate TrkB signalling involve its activation to address neuroprotection or 
psychiatric issues and its suppression in cell proliferative conditions and epileptogenesis (Figure 2). 
The underlying hypothesis is that these disorders are induced or promoted by changes in BDNF/TrkB 
signalling. Correlations between alterations in TrkB signalling in Alzheimer’s disease [107,108], 
Huntington’s disease [109,110], Parkinson’s disease [111], Rett syndrome [112], traumatic brain 
injury, [113] and ageing [114] point to the therapeutic potential of TrkB agonists. A limitation of 
exogenous neurotrophin administration is the cross-activation of nociceptors either directly or through 
p75NTR and also inducing inflammation [115,116]. Inability to deliver BDNF specifically to the 
target cells in sufficient quantities further exacerbates the problem. BDNF is extremely unstable in 
blood and does not penetrate the blood-brain barrier [117,118]. It is also susceptible to proteolytic 
cleavage and does not have a long half life in blood [119]. These limitations have prompted  
the development of various agonists and antagonists of TrkB to regulate the TrkB signalling.  
Synthetic or natural compounds, peptide mimetics or customised antibodies which can specifically 
stimulate or inhibit the TrkB receptors will be of great therapeutic relevance and are being studied 
extensively [120,121].  
BDNF mimetics have been shown to activate TrkB signalling and prevent neuronal degeneration in 
rodents [2]. 7,8-dihydroxyflavone is a potent TrkB agonist which promotes TrkB signalling, ameliorates 
the memory defects in experimental model of Alzheimer’s disease and enhances synaptic plasticity in 
ageing [122]. It also enhances RGC survival [121], neuromuscular transmission [123] and therapeutic 
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efficacy in mouse model of Rett syndrome, promotes neurogenesis and exhibits antidepressant  
effects [124,125]. It was found to reverse memory defects in mouse model of Alzheimer’s disease, 
suppress BACE1 elevation and inhibit amyloid β production [126]. Drugs like memantine significantly 
enhance BDNF/TrkB expression and thereby promote TrkB pathways in Alzheimer’s, Huntington’s, 
Parkinson’s disease and glaucoma [95,96,109,111,127]. Treatment with acetylcholinesterase inhibitors 
such as donepezil and galantamine rapidly activates the TrkB receptor signalling in the mouse 
hippocampus [128]. The toxic effects of amyloid β peptide aggregation [129,130] can be averted by 
the upregulation of TrkB signalling [131]. Deoxygedunin is another compound which is potent and 
specific agonist of TrkB and has been shown to be neuroprotective [132]. Some BDNF mimetic 
peptides have been designed which promote the neuronal survival in a TrkB independent manner. 
Although the exact mechanism of these TrkB independent actions is not known, these may arise from 
the binding of such peptides to the BDNF binding region of other neurotrophin receptors/p75NTR 
leading to downstream activation of NF-κB signalling [133,134]. 
In the visual system, TrkB mAb therapy triggers TrkB activation, protects retina and delays RGC 
death in experimental glaucoma [135]. Fibroblast growth factor-2 when applied to the optic nerve after 
axotomy up-regulates BDNF and TrkB in RGCs by activating the Erk and Protein Kinase-A (PKA) 
signalling pathways [136]. TrkB gene therapy markedly promoted RGC survival after optic nerve 
axotomy indicating that BDNF/TrkB axis activation can be used to protect RGCs in several optic 
neuropathies [47]. Interestingly, repeated administration of BDNF induces inflammation, 
downregulates TrkB expression in RGCs and accelerates their loss and hence it is more important to 
develop safer BDNF mimetic molecules and other mechanism based alternative therapeutic strategies 
to enhance TrkB signalling [137]. Our studies demonstrated that Shp2 phosphatase regulates  
TrkB signalling in RGCs. Inhibiting Shp2 expression may be a novel strategy to enhance the TrkB 
signalling [60]. In the RGCs TrkB activates both the PI3K/Akt and Erk1/2 pathways, but Erk1/2 
appears to be primarily responsible for promoting the survival of RGCs [47]. Specifically promoting 
the Erk1/2 may be helpful to rescue RGCs in glaucoma and other optic nerve degenerative conditions. 
The findings that TrkB is important for long term survival, differentiation, and function of neurons 
in the hippocampus [138], and that several antidepressant treatments not only induce hippocampal 
neurogenesis but that blockade of hippocampal neurogenesis inhibits their antidepressant effects, 
suggest that TrkB agonists might open new treatment avenues for this problem [139]. N-acetyl 
serotonin activates TrkB in a circadian manner and exhibits antidepressant effects. It also enhances 
neurogenesis in the hippocampus [140]. Accumulative evidence suggests that antidepressant drugs 
such as fluoxetine, citalopram, amitryptyline, reboxetine etc. act by upregulating BDNF expression in 
the brain leading to enhanced TrkB signalling while other studies suggest that antidepressant drugs 
may also transactivate TrkB receptors in the brain independent of their effects on BDNF expression [141]. 
Lithium which has long been used for the management of bipolar disorders and mood stabilisation 
enhances BDNF expression and activates TrkB receptor in the cortical neurons which imparts 
neuroprotection against glutamate excitotoxicity [142]. Electrical stimulation of vagus nerve is used as 
a strategy to treat depression and this leads to sustained activation of TrkB receptor in the hippocampal 
region of brain [143]. Electrical stimulation accelerates BDNF/TrkB expression and promotes axonal 
regeneration in the motor neurons [144]. TrkB signalling is also enhanced by diet and exercise 
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regulation. Modulation of TrkB signalling could also have a therapeutic role in management of obesity 
or anorexia [145].  
Conversely, Trk signalling pathways can be targeted with selective inhibitors to potentially treat 
neuroblastomas and other tumours [146]. TrkB signalling inhibition could provide a novel therapy for 
human choriocarcinoma cell proliferation [147]. TrkB inhibitor K252a can potentially be used as an 
anoikis-sensitizing agent in nasopharyngeal carcinoma [148]. Its inhibition has been suggested as an 
attractive target for the treatment of chemotherapy-resistant head and neck squamous cell carcinoma [149]. 
A potent peptide antagonist, cyclotraxin-B reduces TrkB activation [121]. Enhancing p75NTR 
expression also may have a regulatory effect on TrkB actions [150]. Lingo-1 upregulation blocks TrkB 
functions and may be useful in the management of cancers of neuronal origins. Alternatively, blocking 
Lingo-1 in retina reduces RhoA GTPase and JNK activation and enhances Akt signalling in increased 
intra-ocular pressure animal models and thus play a neuroprotective role [151,152]. Corticosterone has 
been shown to negatively regulate BDNF expression in the hippocampus and lowering corticosterone 
levels restores BDNF/TrkB expression [153] which may find implications in neurological disorders 
characterised by seizures. VEGF expression is shown to be directly related to the BDNF/TrkB 
signalling [154,155]. Regulation of BDNF/TrkB signalling can therefore be used as a deliberate 
strategy to control VEGF signalling in angiogenesis and vascular proliferative disorders [156]. 
Similarly, VEGF has been shown to play a role in the regulation of neurotrophin signalling [157]. It 
will be interesting to determine how neurotrophin signalling cross-talks with angiogenic factors and 
how judiciously manipulating one pathway would affect the other for eventual therapeutic purposes.  
6. Conclusions 
To summarise, the TrkB pathway represents a critical and complex signalling network that is of 
great relevance to the understanding of pathophysiology of several proliferative, neurodegenerative 
and psychiatric disorders and to the potential design of next generation therapeutic interventions and 
combination therapies. Despite significant progress in the field of BDNF/TrkB signalling, our 
understanding of the central role of this network in various biochemical and physiological processes in 
various neuronal and non-neuronal tissues, involvement in a range of disease conditions and potential 
to alter specific components of this network for therapeutic applications is very limited. In this review, 
we have highlighted the current understanding of mechanisms regulating TrkB receptor activation and 
the signalling processes mediated by it. Aberrations in TrkB signalling lead to various neuropsychiatric 
and neurodegenerative disorders on one hand and proliferative conditions and epileptogenesis on the 
other. Ability to fine-tune the balance of TrkB signalling and various effectors of this complex network 
in vivo to our advantage using specific agonists and inhibitors could advance our knowledge in a range 
of aforementioned disease conditions. Remarkably, studying the interactions of neurotrophic factor 
signalling with angiogenic factors like VEGF would also open up new avenues in the understanding 
and control of several vascular proliferative and neurodegenerative diseases alike. 
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